With an eye on the rising demand for innovative dosing solutions, Catalent is expanding its capabilities in controlled-release manufacturing, planning to spend $35 million to expand a Kentucky facility.
Almac is expanding its contract manufacturing presence in Ireland, spending about $21.5 million to bolster a production facility and add 229 jobs.
Banner acquisition gives Patheon four new plants and 1,200 additional employees, which the company hopes will help it cross $1 billion in annual revenue this year.
Boehringer Ingelheim sees a wealth of opportunity in China's burgeoning pharma scene, and the German drug giant is plotting to open a contract manufacturing facility in Shanghai to cash in on biologics demand.
French contract manufacturer Unither has acquired a Rochester, NY, facility from Belgium's UCB, planning to keep all 250 employees and 50 contract workers.
CMO UPM Pharmaceuticals is buying a 500,000-square-foot plant from Pfizer for an undisclosed sum, a huge boost to its capacity that comes paired with a big-name new client.
Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.
Navidea Biopharmaceuticals has seen its fair share of CMO troubles, as problems with its last contract manufacturer delayed a much-anticipated FDA approval. Now, the diagnostics developer is hitching up with Nordion to manufacture an in-development imaging agent, hoping to avoid more production setbacks.
The agenda for the mammalian synthetic biology workshop held at the Massachusetts Institute of Technology last weekend demonstrates that renewed interest in vaccines has opened up new therapeutic targets, which in turn has driven new approaches to manufacturing. And the threats of pandemic flu and bioterrorism have acted as an extra innovation driver.
PRA has cut the ribbon on a new facility in Wales, planning to add about 100 new jobs in its informatics unit with help from the local government.